VRN 11
Alternative Names: VRN-11; VRN-110755Latest Information Update: 08 Sep 2025
At a glance
- Originator Voronoi
- Class Antineoplastics; Small molecules
- Mechanism of Action Epidermal growth factor receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase I Non-small cell lung cancer
Most Recent Events
- 25 Aug 2025 Voronoi plans a phase I trial (In volunteers) in Australia (PO, Capsule) in August 2025 (NCT07141381)
- 25 Apr 2025 Pharmacodynamics and pharmacokinetics data from a phase-I trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)
- 25 Apr 2025 Pharmacodynamics data from a preclinical trial in Non-small cell lung cancer presented at the 116th Annual Meeting of the American Association for Cancer Research (AACR-2025)